Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment

Cephalalgia

Volumn 33, Issue 1, 2013, Pages 52-64

  Johnson, Jacinta L ^a   Hutchinson, Mark R ^a   Williams, Desmond B ^b   Rolan, Paul ^a,c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^c ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

codeine; cytokines; glia; ibudilast; Medication overuse headache; opioid induced hyperalgesia

Indexed keywords

ACETYLSALICYLIC ACID; CODEINE; DIZOCILPINE; ERGOTAMINE; FENTANYL; IBUDILAST; IBUPROFEN; KETAMINE; MAGNESIUM; MINOCYCLINE; MORPHINE; NALTREXONE; NEUROTRANSMITTER; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; SECBUTABARBITAL; SUFENTANIL; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ALLODYNIA; BEHAVIOR; CHRONIC PAIN; DISEASE COURSE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG TARGETING; ENDOCRINE DISEASE; GENETIC SUSCEPTIBILITY; HUMAN; HYPERALGESIA; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NOCICEPTION; OPIOID INDUCED HYPERALGESIA; PATHOPHYSIOLOGY; PREVALENCE; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; RISK FACTOR; TREATMENT PLANNING;

ANALGESICS, OPIOID; HEADACHE; HUMANS; HYPERALGESIA; NEUROGLIA;

EID: 84871601949     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1177/0333102412467512     Document Type: Review

References (144)

1. Wang SJ, Fuh JL. Medication overuse headache in Taiwan. Cephalalgia. 2008 ; 28: 1240-1242
2. Pascual J, Mateos V, Gracia M, et al. Medication overuse headache in Spain. Cephalalgia. 2008 ; 28: 1234-1236
3. Bigal M, Lipton R. Excessive acute migraine medication use and migraine progression. Neurology. 2008 ; 71: 1821-1828
4. Zeeberg P, Olesen J, Jensen R. Probable medication-overuse headache: The effect of a 2-month drug-free period. Neurology. 2006 ; 66: 1894-1898 (Pubitemid 44049823)
5. Bigal ME, Lipton RB. Excessive opioid use and the development of chronic migraine. Pain. 2009 ; 142: 179-182
6. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol. 2010 ; 9: 391-401
7. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia. 2006 ; 26: 742-746
8. The international classification of headache disorders: 2nd edition. Cephalalgia. 2004 ; 24 (Suppl 1). 1-160
9. Lantéri-Minet M, Duru G, Mudge M, et al. Quality of life impairment, disability and economic burden associated with chronic daily headache, focusing on chronic migraine with or without medication overuse: A systematic review. Cephalalgia. 2011 ; 31: 837-850
10. Rapoport A, Stang P, Gutterman DL, et al. Analgesic rebound headache in clinical practice: Data from a physician survey. Headache. 1996 ; 36: 14-19 (Pubitemid 26045865)
11. Jensen R, Bendtsen L. Medication overuse headache in Scandinavia. Cephalalgia. 2008 ; 28: 1237-1239
12. Meskunas C, Tepper S, Rapoport A, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006 ; 46: 766-772
13. Lipton R, Bigal M. Chronic daily headache: Is analgesic overuse a cause or a consequence?. Neurology. 2003 ; 61: 154-155 (Pubitemid 36875291)
14. Bahra A, Walsh M, Menon S, et al. Does chronic daily headache arise de novo in association with regular use of analgesics?. Headache. 2003 ; 43: 179-190 (Pubitemid 36348764)
15. Wilkinson S, Becker W, Heine J. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache. 2001 ; 41: 303-309 (Pubitemid 32242617)
16. Diener HC, Limmroth V. Medication-overuse headache: A worldwide problem. Lancet Neurol. 2004 ; 3: 475-483 (Pubitemid 38903098)
17. Scher A, Lipton R, Stewart W, et al. Patterns of medication use by chronic and episodic headache sufferers in the general population: Results from the frequent headache epidemiology study. Cephalalgia. 2010 ; 30: 321-328
18. Bigal ME, Serrano D, Buse D, et al. Wolff Award of the American Headache Society. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache. 2008 ; 48: 1157-1168
19. Perrotta A, Serrao M, Sandrini G, et al. Sensitisation of spinal cord pain processing in medication overuse headache involves supraspinal pain control. Cephalalgia. 2010 ; 30: 272-284
20. Meng ID, Dodick D, Ossipov MH, et al. Pathophysiology of medication overuse headache: Insights and hypotheses from preclinical studies. Cephalalgia. 2011 ; 31: 851-860
21. Bongsebandhu-phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: Implications from animal studies. Curr Pain Headache Rep. 2012 ; 16: 110-115
22. Saper J, Hamel R, Lake AE III. Medication overuse headache (MOH) is a biobehavioural disorder. Cephalalgia. 2005 ; 25: 545-546 (Pubitemid 40896021)
23. Radat F, Creac'h C, Swendsen J, et al. Psychiatric comorbidity in the evolution from migraine to medication overuse headache. Cephalalgia. 2005 ; 25: 519-522 (Pubitemid 40896016)
24. Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009 ; 49: 412-418
25. Park JW, Kim JS, Kim YI, et al. Serotonergic activity contributes to analgesic overuse in chronic tension-type headache. Headache. 2005 ; 45: 1229-1235
26. Cevoli S, Mochi M, Scapoli C, et al. A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol. 2006 ; 13: 1009-1013 (Pubitemid 44284910)
27. Di Lorenzo C, Di Lorenzo G, Sances G, et al. Drug consumption in medication overuse headache is influenced by brain-derived neurotrophic factor Val66Met polymorphism. J Headache Pain. 2009 ; 10: 349-355
28. Di Lorenzo C, Sances G, Di Lorenzo G, et al. The wolframin His611Arg polymorphism influences medication overuse headache. Neurosci Lett. 2007 ; 424: 179-184 (Pubitemid 47411605)
29. Srikiatkhachorn A, Maneesri S, Govitrapong P, et al. Derangement of serotonin system in migrainous patients with analgesic abuse headache: Clues from platelets. Headache. 1998 ; 38: 43-49 (Pubitemid 28125008)
30. Srikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesic-induced headache. Cephalalgia. 1996 ; 16: 419-422 (Pubitemid 26338472)
31. Hering R, Glover V, Pattichis K, et al. 5HT in migraine patients with medication-induced headache. Cephalalgia. 1993 ; 13: 410-412 (Pubitemid 24017457)
32. Srikiatkhachorn A, Tarasub N, Govitrapong P. Effect of chronic analgesic exposure on the central serotonin system: A possible mechanism of analgesic abuse headache. Headache. 2000 ; 40: 343-350 (Pubitemid 30332035)
33. Cupini LM, Costa C, Sarchielli P, et al. Degradation of endocannabinoids in chronic migraine and medication overuse headache. Neurobiol Dis. 2008 ; 30: 186-189
34. Rossi C, Pini L, Cupini M, et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: Relation with serotonin levels. Eur J Clin Pharmacol. 2008 ; 64: 1-8
35. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid. Cephalalgia. 2008 ; 28: 714-722 (Pubitemid 351799744)
36. Abs R, Verhelst J, Maeyaert J, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000 ; 85: 2215-2222 (Pubitemid 32269246)
37. Daniell HW. Opioid endocrinopathy in women consuming prescribed sustained-action opioids for control of nonmalignant pain. J Pain. 2008 ; 9: 28-36 (Pubitemid 350309727)
38. Vuong C, Van Uum SHM, O'Dell LE, et al. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010 ; 31: 98-132
39. Rainero I, Ferrero M, Rubino E, et al. Endocrine function is altered in chronic migraine patients with medication-overuse. Headache. 2006 ; 46: 597-603
40. Srikiatkhachorn A. Chronic daily headache: A scientist's perspective. Headache. 2002 ; 42: 532-537 (Pubitemid 37011830)
41. Ayzenberg I, Obermann M, Nyhuis P, et al. Central sensitization of the trigeminal and somatic nociceptive systems in medication overuse headache mainly involves cerebral supraspinal structures. Cephalalgia. 2006 ; 26: 1106-1114 (Pubitemid 44199402)
42. Collin E, Cesselin F. Neurobiological mechanisms of opioid tolerance and dependence. Clin Neuropharmacol. 1991 ; 14: 465-488
43. Di Chiara G, North RA. Neurobiology of opiate abuse. Trends Pharmacol Sci. 1992 ; 13: 185-193
44. Ueda H, Ueda M. Mechanisms underlying morphine analgesic tolerance and dependence. Front Biosci. 2009 ; 14: 5260-5272
45. Li T, Hou Y, Cao W, et al. Role of dopamine D3 receptors in basal nociception regulation and in morphine-induced tolerance and withdrawal. Brain Res. 2012 ; 1433: 80-84
46. Tompkins DA, Campbell CM. Opioid-induced hyperalgesia: Clinically relevant or extraneous research phenomenon?. Curr Pain Headache Rep. 2011 ; 15: 129-136
47. Fishbain DA, Cole B, Lewis JE, et al. Do opioids induce hyperalgesia in humans? An evidence-based structured review. Pain Med. 2009 ; 10: 829-839
48. Li X, Angst MS, Clark JD. Opioid-induced hyperalgesia and incisional pain. Anesth Analg. 2001 ; 93: 204-209 (Pubitemid 32601180)
49. Li X, Angst MS, Clark JD. A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res. 2001 ; 86: 56-62 (Pubitemid 32124758)
50. Laulin JP, Célèrier E, Larcher A, et al. Opiate tolerance to daily heroin administration: An apparent phenomenon associated with enhanced pain sensitivity. Neurosci. 1999 ; 89: 631-636 (Pubitemid 29070990)
51. Célèrier E, Rivat C, Jun Y, et al. Long-lasting hyperalgesia induced by fentanyl in rats: Preventive effect of ketamine. Anesthesiology. 2000 ; 92: 465-472 (Pubitemid 30078345)
52. Cabañero D, Campillo A, Célérier E, et al. Pronociceptive effects of remifentanil in a mouse model of postsurgical pain: Effect of a second surgery. Anesthesiology. 2009 ; 111: 1334-1345
53. Guignard B, Bossard AE, Coste C, et al. Acute opioid tolerance: Intraoperative remifentanil increases postoperative pain and morphine requirement. Anesthesiology. 2000 ; 93: 409-417 (Pubitemid 30620314)
54. Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: Effect of long-acting maintenance agent. Drug Alcohol Depend. 2001 ; 63: 139-146 (Pubitemid 32488928)
55. Doverty M, White JM, Somogyi AA, et al. Hyperalgesic responses in methadone maintenance patients. Pain. 2001 ; 90: 91-96 (Pubitemid 32146561)
56. Krishnan S, Salter A, Sullivan T, et al. Comparison of pain models to detect opioid-induced hyperalgesia. J Pain Res. 2012 ; 5: 99-106
57. Ramasubbu C, Gupta A. Pharmacological treatment of opioid-induced hyperalgesia: A review of the evidence. J Pain Palliat Care Pharmacother. 2011 ; 25: 219-230
58. Sjøgren P, Jensen NH, Jensen TS. Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists. Pain. 1994 ; 59: 313-316 (Pubitemid 24348916)
59. Devulder J. Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol. 1997 ; 9: 146-148 (Pubitemid 27157383)
60. Wilson GR, Reisfield GM. Morphine hyperalgesia: A case report. Am J Hosp Palliat Care. 2003 ; 20: 459-461 (Pubitemid 39387674)
61. Baron MJ, McDonald PW. Significant pain reduction in chronic pain patients after detoxification from high-dose opioids. J Opioid Manag. 2006 ; 2: 277-282
62. Vorobeychik Y, Chen L, Bush MC, et al. Improved opioid analgesic effect following opioid dose reduction. Pain Med. 2008 ; 9: 724-727
63. Okon TR, George ML. Fentanyl-induced neurotoxicity and paradoxic pain. J Pain Symptom Manage. 2008 ; 35: 327-333
64. Chu L, Clark D, Angst M. Opioid tolerance and hyperalgesia in chronic pain patients after one month of oral morphine therapy: A preliminary prospective study. J Pain. 2006 ; 7: 43-48 (Pubitemid 43097262)
65. Hooten WM, Mantilla CB, Sandroni P, et al. Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering. Pain Med. 2010 ; 11: 1587-1598
66. Chu LF, D'Arcy N, Brady C, et al. Analgesic tolerance without demonstrable opioid-induced hyperalgesia: A double-blinded, randomized, placebo-controlled trial of sustained-release morphine for treatment of chronic nonradicular low-back pain. Pain. 2012 ; 153: 1583-1592
67. Rolan P, Johnson JL, Williams DB, et al. No evidence of opioid-induced hyperalgesia in codeine users. Presented at: 29th Annual Scientific Meeting of the Australian Pain Society, 5-9 April 2009, Sydney, Australia.
68. Chu LF, Angst MS, Clark D. Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations. Clin J Pain. 2008 ; 24: 479-496
69. Chen ZR, Somogyi AA, Bochner F. Polymorphic O-demethylation of codeine. Lancet. 1988 ; 2: 914-915
70. Becker WJ, Purdy RA. Medication overuse headache in Canada. Cephalalgia. 2008 ; 28: 1218-1220
71. Ravishankar K. Medication overuse headache in India. Cephalalgia. 2008 ; 28: 1223-1226
72. Andrews HL. The effect of opiates on the pain threshold in post-addicts. J Clin Invest. 1943 ; 22: 511-516
73. Minville V, Fourcade O, Girolami JP, et al. Opioid-induced hyperalgesia in a mice model of orthopaedic pain: Preventive effect of ketamine. Br J Anaesth. 2010 ; 104: 231-238
74. Mert T, Gunes Y, Ozcengiz D, et al. Magnesium modifies fentanyl-induced local antinociception and hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol. 2009 ; 380: 415-420
75. Waxman AR, Arout C, Caldwell M, et al. Acute and chronic fentanyl administration causes hyperalgesia independently of opioid receptor activity in mice. Neurosci Lett. 2009 ; 462: 68-72
76. Juni A, Klein G, Kest B. Morphine hyperalgesia in mice is unrelated to opioid activity, analgesia, or tolerance: Evidence for multiple diverse hyperalgesic systems. Brain Res. 2006 ; 1070: 35-44 (Pubitemid 43247742)
77. van Dorp ELA, Kest B, Kowalczyk WJ, et al. Morphine-6beta-glucuronide rapidly increases pain sensitivity independently of opioid receptor activity in mice and humans. Anesthesiology. 2009 ; 110: 1356-1363
78. Chen ZR, Irvine RJ, Somogyi AA, et al. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci. 1991 ; 48: 2165-2171
79. Bartlett SE, Dodd PR, Smith MT. Pharmacology of morphine and morphine-3-glucuronide at opioid, excitatory amino acid, GABA and glycine binding sites. Pharmacol Toxicol. 1994 ; 75: 73-81 (Pubitemid 24257448)
80. Bartlett SE, Cramond T, Smith MT. The excitatory effects of morphine-3-glucuronide are attenuated by LY274614, a competitive NMDA receptor antagonist, and by midazolam, an agonist at the benzodiazepine site on the GABAA receptor complex. Life Sci. 1994 ; 54: 687-694
81. Labella FS, Pinsky C, Havlicek V. Morphine derivatives with diminished opiate receptor potency show enhanced central excitatory activity. Brain Res. 1979 ; 174: 263-271 (Pubitemid 9229563)
82. Hutchinson MR, Shavit Y, Grace PM, et al. Exploring the neuroimmunopharmacology of opioids: An integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol Rev. 2011 ; 63: 772-810
83. Bartley J. Could glial activation be a factor in migraine?. Med Hypotheses. 2009 ; 72: 255-257
84. Clark A, Yip P, Grist J, et al. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007 ; 104: 10655-10660 (Pubitemid 47185720)
85. DeLeo JA, Sorkin LS, Watkins LR Immune and glial regulation of pain. Seattle: IASP Press ; 2007 :
86. Milligan E, Sloane E, Watkins L. Glia in pathological pain: A role for fractalkine. J Neuroimmunol. 2008 ; 198: 113-120
87. Ren K, Dubner R. Neuron-glia crosstalk gets serious: Role in pain hypersensitivity. Curr Opin Anaesthesiol. 2008 ; 21: 570-579
88. Watkins L, Hutchinson M, Milligan ED, et al. "Listening" and "talking" to neurons: Implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev. 2007 ; 56: 148-169 (Pubitemid 350100866)
89. Milligan E, Watkins L. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci. 2009 ; 10: 23-36
90. Watkins L, Maier S. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov. 2003 ; 2: 973-985 (Pubitemid 37540579)
91. Eriksson NP, Persson JK, Aldskogius H, et al. A quantitative analysis of the glial cell reaction in primary sensory termination areas following sciatic nerve injury and treatment with nerve growth factor in the adult rat. Exp Brain Res. 1997 ; 114: 393-404 (Pubitemid 27214244)
92. Watkins L, Hutchinson M, Rice K, et al. The "toll" of opioid-induced glial activation: Improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci. 2009 ; 30: 581-591
93. White FA, Jung H, Miller RJ. Chemokines and the pathophysiology of neuropathic pain. Proc Natl Acad Sci U S A. 2007 ; 104: 20151-20158
94. Chao CC, Gekker G, Sheng WS, et al. Priming effect of morphine on the production of tumor necrosis factor-alpha by microglia: Implications in respiratory burst activity and human immunodeficiency virus-1 expression. J Pharmacol Exp Ther. 1994 ; 269: 198-203 (Pubitemid 24143254)
95. Hains LE, Loram LC, Weiseler JL, et al. Pain intensity and duration can be enhanced by prior challenge: Initial evidence suggestive of a role of microglial priming. J Pain. 2010 ; 11: 1004-1014
96. Frank MG, Watkins LR, Maier SF. Stress- and glucocorticoid-induced priming of neuroinflammatory responses: Potential mechanisms of stress-induced vulnerability to drugs of abuse. Brain Behav Immun. 2011 ; 25 (Suppl 1). S21 - S28
97. Wei F, Guo W, Zou S, et al. Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci. 2008 ; 28: 10482-10495
98. Meller ST, Dykstra C, Grzybycki D, et al. The possible role of glia in nociceptive processing and hyperalgesia in the spinal cord of the rat. Neuropharmacology. 1994 ; 33: 1471-1478 (Pubitemid 24353743)
99. Watkins L, Martin D, Ulrich P, et al. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain. 1997 ; 71: 225-235 (Pubitemid 27288136)
100. Milligan ED, Mehmert KK, Hinde JL, et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency virus-1 (HIV-1) envelope glycoprotein, gp120. Brain Res. 2000 ; 861: 105-116 (Pubitemid 30177288)
101. Milligan ED, Twining C, Chacur M, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci. 2003 ; 23: 1026-1040 (Pubitemid 36206195)
102. Ledeboer A, Liu T, Shumilla JA, et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2006 ; 2: 279-291 (Pubitemid 47074741)
103. Hama AT, Broadhead A, Lorrain DS, et al. The antinociceptive effect of the asthma drug ibudilast in rat models of peripheral and central neuropathic pain. J Neurotrauma. 2012 ; 29: 600-610
104. Tanga FY, Nutile-McMenemy N, DeLeo JA. The CNS role of toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A. 2005 ; 102: 5856-5861 (Pubitemid 40559649)
105. Bettoni I, Comelli F, Rossini C, et al. Glial TLR4 receptor as new target to treat neuropathic pain: Efficacy of a new receptor antagonist in a model of peripheral nerve injury in mice. Glia. 2008 ; 56: 1312-1319
106. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: Involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008 ; 28: 20-29
107. Hutchinson MR, Loram LC, Zhang Y, et al. Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience. 2010 ; 168: 551-563
108. Okun E, Griffioen KJ, Mattson MP. Toll-like receptor signaling in neural plasticity and disease. Trends Neurosci. 2011 ; 34: 269-281
109. Lehnardt S, Massillon L, Follett P, et al. Activation of innate immunity in the CNS triggers neurodegeneration through a toll-like receptor 4-dependent pathway. Proc Natl Acad Sci U S A. 2003 ; 100: 8514-8519 (Pubitemid 36842576)
110. Jou I, Lee JH, Park SY, et al. Gangliosides trigger inflammatory responses via TLR4 in brain glia. Am J Pathol. 2006 ; 168: 1619-1630
111. Tang S-C, Arumugam TV, Xu X, et al. Pivotal role for neuronal toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A. 2007 ; 104: 13798-13803 (Pubitemid 350003400)
112. Nicotra L, Loram LC, Watkins LR, et al. Toll-like receptors in chronic pain. Exp Neurol. 2012 ; 234: 316-329
113. Schmitz G, Leuthäuser-Jaschinski K, Orsó E. Are circulating monocytes as microglia orthologues appropriate biomarker targets for neuronal diseases?. Cent Nerv Syst Agents Med Chem. 2009 ; 9: 307-330
114. Kwok Y, Hutchinson M, Gentgall M, et al. Increased responsiveness of peripheral blood mononuclear cells to in vitro TLR 2, 4 and 7 ligand stimulation in chronic pain patients. PLos One. 2012 ; 7: e44232 - e44232
115. Hutchinson MR, Bland ST, Johnson KW, et al. Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal. 2007 ; 7: 98-111 (Pubitemid 350292608)
116. Hutchinson MR, Northcutt AL, Chao LW, et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia. Brain Behav Immun. 2008 ; 22: 1248-1256
117. Hutchinson MR, Zhang Y, Shridhar M, et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects. Brain Behav Immun. 2010 ; 24: 83-95
118. Bartley J, Watkins L. Comment on: Excessive opioid use and the development of chronic migraine. Pain. 2009 ; 145: 262-263
119. Due MR, Piekarz AD, Wilson N, et al. Neuroexcitatory effects of morphine-3-glucuronide are dependent on toll-like receptor 4 signaling. J Neuroinflammation. 2012 ; 9: 200-200
120. Lance F, Parkes C, Wilkinson M. Does analgesic abuse cause headaches de novo?. Headache. 1988 ; 28: 61-62 (Pubitemid 18089808)
121. Katsarava Z, Jensen R. Medication-overuse headache: Where are we now?. Curr Opin Neurol. 2007 ; 20: 326-326
122. Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology. 2006 ; 67: 109-109
123. Thalakoti S, Patil V, Damodaram S, et al. Neuron-glia signaling in trigeminal ganglion: Implications for migraine pathology. Headache. 2007 ; 47: 1008-1023 (Pubitemid 47057221)
124. Tension-type headache: Mechanisms. Nappi G Moskowitz MA, ed. Edinburgh: Elsevier ; 2010: 359-359.
125. Bendtsen L. Review: Drug and nondrug treatment in tension-type headache. Ther Adv Neurol Disord. 2009 ; 2: 155-161
126. Ashina S, Bendtsen L, Jensen R. Analgesic effect of amitriptyline in chronic tension-type headache is not directly related to serotonin reuptake inhibition. Pain. 2004 ; 108: 108-114 (Pubitemid 38251679)
127. Meng ID, Cao L. From migraine to chronic daily headache: The biological basis of headache transformation. Headache. 2007 ; 47: 1251-1258 (Pubitemid 47457813)
128. Rozen T, Swidan S. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007 ; 47: 1050-1055 (Pubitemid 47057216)
129. Papandreou O, Soldatou A, Tsitsika A, et al. Serum S100β protein in children with acute recurrent headache: A potentially useful marker for migraine. Headache. 2005 ; 45: 1313-1316 (Pubitemid 350004944)
130. Hershey A, Burdine D, Kabbouche M, et al. Genomic expression patterns in medication overuse headaches. Cephalalgia. 2010 ; 31: 161-171
131. Wieseler JL, Mcfadden A, Miles N, et al Facial allodynia potentiation by supradural inflammatory mediators and morphine: A model of medication overuse headache. Program No. 178.09/NN19 2011 Neuroscience meeting planner. Washington, DC: Society for Neuroscience ; 2011. :
132. Wieseler JL, Mcfadden A, Brown K, et al Facial allodynia: Involvement of glia and potentiation by prior morphine. Program No. 780.4MM4 2010 Neuroscience meeting planner. San Diego, CA: Society for Neuroscience ; 2010. :
133. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010 ; 31: 455-461
134. Munksgaard SB, Bendtsen L. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design. Cephalalgia. 2012 ; 32: 834-844
135. Olesen J. Detoxification is the primary task in overusing patients: Debate at the International Headache Congress, Berlin, June 2011. Cephalalgia. 2012 ; 31: 420-422
136. Diener H-C. Detoxification for medication overuse headache is not necessary. Cephalalgia. 2012 ; 31: 423-427
137. Dunne DW, Shaw A, Bockenstedt LK, et al. Increased TLR4 expression and downstream cytokine production in immunosuppressed adults compared to non-immunosuppressed adults. PLoS One. 2010 ; 5: e11343 - e11343
138. Ledeboer A, Sloane EM, Milligan ED, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain. 2005 ; 115: 71-83
139. Raghavendra V, Tanga F, DeLeo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther. 2003 ; 306: 624-630 (Pubitemid 36886161)
140. Rolan P, Gibbons JA, He L, et al. Ibudilast in healthy volunteers: Safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol. 2008 ; 66: 792-801
141. Rolan P, Hutchinson M, Johnson K. Ibudilast: A review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother. 2009 ; 10: 2897-2904
142. Barkhof F, Hulst H, Drulovic J, et al. Ibudilast in relapsing-remitting multiple sclerosis: A neuroprotectant?. Neurology. 2010 ; 74: 1033-1040
143. Preliminary safety and efficacy of ibudilast in heroin-dependent volunteers: First trial of a glial cell modulator in drug addicts, http://www.globenewswire.com/new.html?d=209012 (13 December 2010, accessed 25 February 2012.
144. Hutchinson MR, Northcutt AL, Hiranita T, et al. Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci. 2012 ; 32: 11187-11200